Lisa Bodei
Memorial Sloan Kettering Cancer Center
Internal medicineRadiologyPathologyOncologyProgressive diseaseNeuroendocrine tumorsDiseaseLiquid biopsyProstate cancerNuclear medicineRadionuclide therapyPeptide receptorIn patientCancer researchMedicineBiomarker (medicine)Chromogranin ASomatostatin receptorGastroenterology
126Publications
25H-index
1,370Citations
Publications 126
Newest
#1Rodney J. Hicks (Peter MacCallum Cancer Centre)H-Index: 90
#2Clarisse Dromain (UNIL: University of Lausanne)H-Index: 60
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 19 authors...
The European Neuroendocrine Tumor Society (ENETS) promotes practices and procedures that aim to improve the standard of care delivered to patients diagnosed with or suspected of having neuroendocrine neoplasia (NEN). At its annual Scientific Advisory Board Meeting in 2018, experts in imaging, pathology and clinical care of patients with NEN drafted guidance for the standardised reporting of diagnostic studies critical to the diagnosis, grading, staging and treatment of NEN. These included pathol...
Source
#1Philippe Ruszniewski (University of Paris)H-Index: 31
#2Martyn Caplin (Royal Free Hospital)H-Index: 71
Last. James C. Yao (University of Texas MD Anderson Cancer Center)H-Index: 74
view all 17 authors...
Source
Source
#1I.M. Modlin (Yale University)
Last. Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
view all 11 authors...
Background null Biomarkers are key tools in cancer management. In neuroendocrine tumors (NETs), Chromogranin A (CgA) was considered acceptable as a biomarker. We compared the clinical efficacy of a multigenomic blood biomarker (NETest) to CgA over a 5-year period. null null null Patients and methods null An observational, prospective, cross-sectional, multicenter, multinational, comparative cohort assessment. Cohort 1: NETest evaluation in NETs (n = 1684) and cancers, benign diseases, controls (...
Source
#1Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
#2Mark KiddH-Index: 66
Last. Irvin M. Modlin (Yale University)H-Index: 81
view all 3 authors...
Abstract null null The recent development of peptide receptor radionuclide therapy (PRRT) into an accepted treatment modality allows for consideration of what needs to be undertaken to move beyond the siege warfare concept of tumor therapy. This chapter therefore seeks to address and resolve the limitations of the “huff and puff” theory of tumor destruction by critically applying the concepts and knowledge of radionuclide therapy. It therefore discusses the advantages of PRRT without ignoring it...
Source
#1Andrew M. ScottH-Index: 87
#2Lisa Bodei (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 25
Source
#1Sonya Youngju Park (St Mary's Hospital)
Last. Erik Mittra (OHSU: Oregon Health & Science University)H-Index: 5
view all 10 authors...
A new era of precision diagnostics and therapy for patients with neuroendocrine neoplasms began with the approval of somatostatin receptor (SSTR) radiopharmaceuticals for positron emission tomography (PET) imaging followed by peptide receptor radionuclide therapy (PRRT). With the transition from SSTR-based gamma scintigraphy to PET, the higher sensitivity of the latter raised questions regarding the direct application of the planar scintigraphy-based Krenning score for PRRT eligibility. Also, to...
Source
#1Jonathan StrosbergH-Index: 12
#2Martyn Caplin (Royal Free Hospital)H-Index: 71
Last. Marianne Pavel (FAU: University of Erlangen-Nuremberg)H-Index: 52
view all 19 authors...
Source
Abstract Biomarkers that are secretory monoanalyte products of GEP (gastro-entero-pancreatic) and BP (broncho-pulmonary) or lung NETs (neuroendocrine tumors) have significant limitations in clinical utility. The assessment of secretory activity provides little information in regard to tumor biology. Furthermore, ∼50% of NETs have measurable secretory products. Molecular genomic identification in blood (NETest liquid biopsy) of the regulators of tumor biology provide multianalyte, real-time asses...
1 CitationsSource
1 CitationsSource